Immutep plans presentation of final survival data from head and neck cancer trial in December
IMMP•Immutep plans to present final overall survival results from the TACTI-003 Part B trial on Dec. 14, 2026, at the ESMO Immuno-Oncology & Advanced Therapies Congress. The trial evaluates first-line treatment for recurrent or metastatic head and neck cancer in patients with PD-L1-negative tumors.
1. Planned presentations
Immutep plans to present survival data from two trials of eftilagimod alfa in combination with Keytruda at international congresses in November and December 2026. EFTISARC-NEO Phase II survival results will be presented at CTOS on Nov. 19, covering radiotherapy before surgery for resectable soft-tissue sarcoma.
2. TACTI-003 results
Final overall survival results from TACTI-003 Part B will be presented on Dec. 14 at the ESMO Immuno-Oncology & Advanced Therapies Congress. The trial evaluates first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma in patients with PD-L1-negative tumors.
